Clinicopathological response and breast conservation in locally advanced breast cancer cases treated with neoadjuvant chemotherapy

  • Received 30.06.2024
  • Revised 17.09.2024
  • Accepted 26.11.2024
  • 940 Views
  • Retrieved from Vol. 10, No. 2, 2024
  • Pages 16-25

Neoadjuvant chemotherapy is crucial for enhancing surgical outcomes and enabling breast conservation in locally advanced breast adenocarcinoma, which is often inoperable. This prospective cohort study aimed to evaluate the clinic-pathological response and breast conservation rates in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. The patients were administered chemotherapy according to a standard protocol and were followed until their surgical outcome. Out of a total of 90 patients with locally advanced breast cancer, 78 were eligible for neoadjuvant therapy. These patients, with a mean (SD) age of 47.5 (9.4) years, were included in the study. Nearly half (52.6%) were post-menopausal; 55% (n = 43) had right breast involvement, and 57.7% (n = 45) had invasive lobular carcinoma. Approximately 47.43% of patients demonstrated a complete clinical response. In comparison, only 37% achieved a pathological complete response, which was not associated with the oestrogen receptor, progesterone receptor, or human epidermal growth factor receptor-2 status (p > 0.05). Patients who achieved a complete clinical response had a higher likelihood of undergoing breast‑conserving surgery (p < 0.05). The study observed that breast conservation rates were improved with neoadjuvant chemotherapy. These findings may assist clinicians in improving treatment outcomes for patients with locally advanced breast cancer

advanced cancer; invasive breast carcinoma; oncological outcomes; breast-conserving surgery

https://doi.org/10.61751/ijmmr/2.2024.16

[1] Cuniolo L, Gipponi M, Murelli F, Depaoli F, Cornacchia C, Franchelli S, et al. Multidisciplinary and tailored treatment of locally advanced breast cancer in progression during neoadjuvant chemotherapy: Case report. Curr Oncol. 2024;31(5):2856–66. DOI: 10.3390/curroncol31050217

[2] Aebi S, Karlsson P, Wapnir IL. Locally advanced breast cancer. The Breast. 2022;62(Suppl 1). DOI: 10.1016/j.breast.2021.12.011

[3] Dhanushkodi M, Sridevi V, Shanta V, Rama R, Swaminathan R, Selvaluxmy G, et al. Locally advanced breast cancer (LABC): Real-world outcome of patients from Cancer Institute, Chennai. JCO Glob Oncol. 2021;7:767–81. DOI: 10.1200/GO.21.00001

[4] Marian D, Fulop ZZ, Fulop RL, Molnar AH, Scurtu A, Andercou O. Locally advanced breast cancer in Eastern European developing countries. Ann Ital Chir. 2023;94:346–50.

[5] Gamal I. Management of a rare case of locally advanced mucinous carcinoma of the breast: A case report. Egypt J Hosp Med. 2023;91(1):5246–50.

[6] Akbari ME, Ghelichi-Ghojogh M, Nikeghbalian Z, Karami M, Akbari A, Hashemi M, et al. Neoadjuvant vs adjuvant chemotherapy in patients with locally advanced breast cancer: A retrospective cohort study. Ann Med Surg (Lond). 2022;84:104921. DOI: 10.1016/j.amsu.2022.104921

[7] Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39(13):1485–1505. DOI: 10.1200/JCO.20.03399

[8] Pandurangappa V, Paruthy SB, Jamwal R, Singh A, Tanwar S, Kumar D, et al. Assessment of response to neoadjuvant chemotherapy in locally advanced breast carcinoma using image-guided clip placement. Cureus. 2023;15(10):e47763. DOI: 10.7759/cureus.47763

[9] Schott K, Majer C, Bulashevska A, Childs L, Schmidt MHH, Rajalingam K, et al. AMHD1 in cancer: Curse or cure? J Mol Med. 2022;100:351–72. DOI: 10.1007/s00109-021-02131-w

[10] Kuhl CK. The changing world of breast cancer: A radiologist's perspective. Invest Radiol. 2015;50(9):615–28. DOI: 10.1097/RLI.0000000000000166

[11] Kuhl CK, Schild HH, Morakkabati N. Dynamic bilateral contrast-enhanced MR imaging of the breast: Trade-off between spatial and temporal resolution. Radiology. 2005;236(3):789–800. DOI: 10.1148/radiol.2363040811

[12] Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019–27. DOI: 10.1200/JCO.2005.04.1665

[13] Lorentzen T, Heidemann LN, Möller S, Bille C. Impact of neoadjuvant chemotherapy on surgical complications in breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2022;48(1):44–52. DOI: 10.1016/j.ejso.2021.09.007

[14] Piñero-Madrona A, Ruiz-Merino G, Bernet L, Miguel-Martínez B, Vicente-García F, Viguri-Díaz MA, et al. Tumoral load quantification of positive sentinel lymph nodes in breast cancer to predict more than two involved nodes. Breast. 2014;23(6):859–64. DOI: 10.1016/j.breast.2014.09.005

[15] Hennigs A, Köpke M, Feißt M, Riedel F, Rezai M, Nitz U, et al. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice? Breast Cancer Res Treat. 2019;173:429–38. DOI: 10.1007/s10549-018-5009-2

[16] Morgan RL, Camidge DR. Reviewing RECIST in the era of prolonged and targeted therapy. J Thorac Oncol. 2018;13(2):154–64. DOI: 10.1016/j.jtho.2017.10.015

[17] Ahmed KA, Correa CR, Dilling TJ, Rao NG, Shridhar R, Trotti AM, et al. Altered fractionation schedules in radiation treatment: A review. Semin Oncol. 2014;41(6):730–50. DOI: 10.1053/J.SEMINONCOL.2014.09.012

[18] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. DOI: 10.1016/j.ejca.2008.10.026

[19] Dawson LA, Ménard C. Imaging in radiation oncology: A perspective. Oncologist. 2010;15(4):338–49. DOI: 10.1634/theoncologist.2009-S106

[20] Watanabe H, Okada M, Kaji Y, Satouchi M, Sato Y, Yamabe Y, et al. New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1). Cancer Chemother. 2009;36(13):2495–501.

[21] Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105–22. DOI: 10.1200/JCO.2018.77.8738

[22] Bhargavan RV, Prasannan N, Krishna KM, Augustine P, Cherian K. The role of level III dissection in locally advanced breast cancer following neoadjuvant chemotherapy – a prospective study. South Asian J Cancer. 2024;13(3):170–6. DOI: 10.1055/s-0043-1777727 

[23] Chabner BA, Longo DL. Cancer chemotherapy, immunotherapy, and biotherapy. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2024. 720 p.

[24] The World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [Internet]. [cited 2024 Apr 30]. Available from: https://www.wma.net/what-we-do/medical-ethics/ declaration-of-helsinki/

[25] Chidley P, Foroudi F, Tacey M, Khor R, Yeh J, Bevington E, et al. Neoadjuvant radiotherapy for locally advanced and high-risk breast cancer. J Med Imaging Radiat Oncol. 2021;65(3):345–53. DOI: 10.1111/1754-9485.13180

[26] Bhattacharyya T, Sharma SC, Yadav BS, Singh R, Singh G. Outcome of neoadjuvant chemotherapy in locally advanced breast cancer: A tertiary care centre experience. Indian J Med Paediatr Oncol. 2014;35(3):215–20. DOI: 10.4103/0971-5851.142038

[27] DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51. DOI: 10.3322/caac.21583

[28] van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: A secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol. 2021;7(7):978–84. DOI: 10.1001/jamaoncol.2021.1371

[29] Kunnuru SKR, Thiyagarajan M, Martin Daniel J, Singh KB. A study on clinical and pathological responses to neoadjuvant chemotherapy in breast carcinoma. Breast Cancer (Dove Med Press). 2020;12:259–66. DOI: 10.2147/BCTT.S277588

[30] Choudhary P, Gogia A, Deo SVS, Mathur S, Sharma D. Neoadjuvant chemotherapy in locally advanced breast cancer: Clinicopathological characteristics and correlation with pathological complete response. JCO. 2020;38:e12658. DOI: 10.1200/JCO.2020.38.15_suppl.e12658

[31] Alawad AA. Evaluation of clinical and pathological response after two cycles of neoadjuvant chemotherapy on Sudanese patients with locally advanced breast cancer. Ethiop J Health Sci. 2014;24(1):15–20. DOI: 10.4314/ejhs.v24i1.2

[32] Curigliano G, Ciruelos E, Kalinsky K, Proudman D, Nellesen D, Lopez P, et al. Short-term risk of recurrence in patients with HR+/HER2− early breast cancer treated with endocrine therapy in randomized clinical trials: A meta-analysis. J Clin Oncol. 2024;42:541. DOI: 10.1200/JCO.2024.42.16_suppl.541

[33] Loibl S, Jackisch C, Lederer B, Untch M, Paepke S, Kümmel S, et al. Outcome after neoadjuvant chemotherapy in young breast cancer patients: A pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Res Treat. 2015;152:377–87. DOI: 10.1007/s10549-015-3479-z

[34] Mermut O, Inanc B, Gursu RU, Arslan E, Trabulus DC, Havare SB, et al. Factors affecting pathological complete response after neoadjuvant chemotherapy in breast cancer: A single-center experience. Rev Assoc Med Bras (1992). 2021;67(6):845–50. DOI: 10.1590/1806-9282.20210114

[35] Agrawal SK, Patel D, Shenoy P, Ahmed R, Arun I, Chatterjee S. Oncologic safety of breast conservation following NACT in women with locally advanced breast cancer. Ecancermedicalscience. 2023;17:1554. DOI: 10.3332/ecancer.2023.1554

[36] Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, et al. Primary surgery with systemic therapy in patients with de novo stage IV breast cancer: 10-year follow-up; protocol MF07-01 randomized clinical trial. J Am Coll Surg. 2021;233(6):742–51.e5. DOI: 10.1016/j.jamcollsurg.2021.08.686

[37] Kwon MR, Choi JS, Won H, Ko EY, Ko ES, Park KW, et al. Breast cancer screening with abbreviated breast MRI: 3-year outcome analysis. Radiology. 2021;299(1):73–83. DOI: 10.1148/radiol.2021202927

[38] Sun Y, Liao M, He L, Zhu C. Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2017;96(43):e8367. DOI: 10.1097/MD.0000000000008367

[39] Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838–48. DOI: 10.1158/1078-0432.CCR-19-3492